These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 28445144)

  • 1. Stroma-derived HGF drives metabolic adaptation of colorectal cancer to angiogenesis inhibitors.
    Mira A; Morello V; Céspedes MV; Perera T; Comoglio PM; Mangues R; Michieli P
    Oncotarget; 2017 Jun; 8(24):38193-38213. PubMed ID: 28445144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Norcantharidin combined with EGFR-TKIs overcomes HGF-induced resistance to EGFR-TKIs in EGFR mutant lung cancer cells via inhibition of Met/PI3k/Akt pathway.
    Wu H; Fan F; Liu Z; Shen C; Wang A; Lu Y
    Cancer Chemother Pharmacol; 2015 Aug; 76(2):307-15. PubMed ID: 26063323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Humanized anti-hepatocyte growth factor (HGF) antibody suppresses innate irinotecan (CPT-11) resistance induced by fibroblast-derived HGF.
    Woo JK; Kang JH; Kim B; Park BH; Shin KJ; Song SW; Kim JJ; Kim HM; Lee SJ; Oh SH
    Oncotarget; 2015 Sep; 6(27):24047-60. PubMed ID: 26090722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer.
    Takeuchi S; Wang W; Li Q; Yamada T; Kita K; Donev IS; Nakamura T; Matsumoto K; Shimizu E; Nishioka Y; Sone S; Nakagawa T; Uenaka T; Yano S
    Am J Pathol; 2012 Sep; 181(3):1034-43. PubMed ID: 22789825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microenvironment-derived HGF overcomes genetically determined sensitivity to anti-MET drugs.
    Pennacchietti S; Cazzanti M; Bertotti A; Rideout WM; Han M; Gyuris J; Perera T; Comoglio PM; Trusolino L; Michieli P
    Cancer Res; 2014 Nov; 74(22):6598-609. PubMed ID: 25217525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors.
    Shojaei F; Lee JH; Simmons BH; Wong A; Esparza CO; Plumlee PA; Feng J; Stewart AE; Hu-Lowe DD; Christensen JG
    Cancer Res; 2010 Dec; 70(24):10090-100. PubMed ID: 20952508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HGF/c-Met pathway is one of the mediators of sunitinib-induced tumor cell type-dependent metastasis.
    Shojaei F; Simmons BH; Lee JH; Lappin PB; Christensen JG
    Cancer Lett; 2012 Jul; 320(1):48-55. PubMed ID: 22269210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CAF-derived HGF promotes cell proliferation and drug resistance by up-regulating the c-Met/PI3K/Akt and GRP78 signalling in ovarian cancer cells.
    Deying W; Feng G; Shumei L; Hui Z; Ming L; Hongqing W
    Biosci Rep; 2017 Apr; 37(2):. PubMed ID: 28258248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BATF2 Deficiency Promotes Progression in Human Colorectal Cancer via Activation of HGF/MET Signaling: A Potential Rationale for Combining MET Inhibitors with IFNs.
    Liu Z; Wei P; Yang Y; Cui W; Cao B; Tan C; Yu B; Bi R; Xia K; Chen W; Wang Y; Zhang Y; Du X; Zhou X
    Clin Cancer Res; 2015 Apr; 21(7):1752-63. PubMed ID: 25762344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic profiling of a Hepatocyte growth factor-dependent signature for MET-targeted therapy in glioblastoma.
    Johnson J; Ascierto ML; Mittal S; Newsome D; Kang L; Briggs M; Tanner K; Marincola FM; Berens ME; Vande Woude GF; Xie Q
    J Transl Med; 2015 Sep; 13():306. PubMed ID: 26381735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors.
    Luraghi P; Reato G; Cipriano E; Sassi F; Orzan F; Bigatto V; De Bacco F; Menietti E; Han M; Rideout WM; Perera T; Bertotti A; Trusolino L; Comoglio PM; Boccaccio C
    Cancer Res; 2014 Mar; 74(6):1857-69. PubMed ID: 24448239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HGF-MET cascade, a key target for inhibiting cancer metastasis: the impact of NK4 discovery on cancer biology and therapeutics.
    Mizuno S; Nakamura T
    Int J Mol Sci; 2013 Jan; 14(1):888-919. PubMed ID: 23296269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SOCS1 inhibits migration and invasion of prostate cancer cells, attenuates tumor growth and modulates the tumor stroma.
    Villalobos-Hernandez A; Bobbala D; Kandhi R; Khan MG; Mayhue M; Dubois CM; Ferbeyre G; Saucier C; Ramanathan S; Ilangumaran S
    Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):36-47. PubMed ID: 27779203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of growth, invasion, and metastasis of human pancreatic carcinoma cells by NK4 in an orthotopic mouse model.
    Tomioka D; Maehara N; Kuba K; Mizumoto K; Tanaka M; Matsumoto K; Nakamura T
    Cancer Res; 2001 Oct; 61(20):7518-24. PubMed ID: 11606388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells.
    Yamada T; Takeuchi S; Nakade J; Kita K; Nakagawa T; Nanjo S; Nakamura T; Matsumoto K; Soda M; Mano H; Uenaka T; Yano S
    Clin Cancer Res; 2012 Jul; 18(13):3592-602. PubMed ID: 22553343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment with Lingqi capsules suppresses colorectal cancer by inhibiting the hepatocyte growth factor/c‑Met signal transduction pathway.
    Wang GS; Zhao JL; Li H
    Mol Med Rep; 2015 Mar; 11(3):1865-70. PubMed ID: 25373931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatocyte growth factor induces resistance to anti-epidermal growth factor receptor antibody in lung cancer.
    Yamada T; Takeuchi S; Kita K; Bando H; Nakamura T; Matsumoto K; Yano S
    J Thorac Oncol; 2012 Feb; 7(2):272-80. PubMed ID: 22089117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.
    Donev IS; Wang W; Yamada T; Li Q; Takeuchi S; Matsumoto K; Yamori T; Nishioka Y; Sone S; Yano S
    Clin Cancer Res; 2011 Apr; 17(8):2260-9. PubMed ID: 21220474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nicotine Reduces Survival via Augmentation of Paracrine HGF-MET Signaling in the Pancreatic Cancer Microenvironment.
    Delitto D; Zhang D; Han S; Black BS; Knowlton AE; Vlada AC; Sarosi GA; Behrns KE; Thomas RM; Lu X; Liu C; George TJ; Hughes SJ; Wallet SM; Trevino JG
    Clin Cancer Res; 2016 Apr; 22(7):1787-99. PubMed ID: 26667487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Depleting MET-Expressing Tumor Cells by ADCC Provides a Therapeutic Advantage over Inhibiting HGF/MET Signaling.
    Hultberg A; Morello V; Huyghe L; De Jonge N; Blanchetot C; Hanssens V; De Boeck G; Silence K; Festjens E; Heukers R; Roux B; Lamballe F; Ginestier C; Charafe-Jauffret E; Maina F; Brouckaert P; Saunders M; Thibault A; Dreier T; de Haard H; Michieli P
    Cancer Res; 2015 Aug; 75(16):3373-83. PubMed ID: 26141862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.